Immutep to Participate in Upcoming Investor Conferences
Immutep (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotech company focused on LAG-3 immunotherapies for cancer and autoimmune diseases, has announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024, and the Baird 2024 Global Healthcare Conference in New York on September 10, 2024.
At the Canaccord event, Immutep's presentation is scheduled for 8:30-8:55 AM ET, while at the Baird conference, it will present from 1:25-1:55 PM ET. A live webcast and replay of the Canaccord presentation will be available on Immutep's website and through a provided link.
Immutep (ASX: IMM; NASDAQ: IMMP), una società biotecnologica in fase clinica focalizzata sulle immunoterapie LAG-3 per il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda presenterà al 44° Annual Growth Conference di Canaccord Genuity a Boston il 14 agosto 2024 e al Baird 2024 Global Healthcare Conference a New York il 10 settembre 2024.
All'evento di Canaccord, la presentazione di Immutep è programmata dalle 8:30 alle 8:55 AM ET, mentre alla conferenza di Baird si esibirà dalle 1:25 alle 1:55 PM ET. Una diretta streaming e la registrazione della presentazione di Canaccord saranno disponibili sul sito web di Immutep e tramite un link fornito.
Immutep (ASX: IMM; NASDAQ: IMMP), una compañía biotecnológica en etapa clínica centrada en inmunoterapias LAG-3 para el cáncer y enfermedades autoinmunitarias, ha anunciado su participación en dos próximas conferencias para inversores. La compañía se presentará en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston el 14 de agosto de 2024, y en la Conferencia Global de Salud 2024 de Baird en Nueva York el 10 de septiembre de 2024.
En el evento de Canaccord, la presentación de Immutep está programada para las 8:30-8:55 AM ET, mientras que en la conferencia de Baird, se presentará de 1:25 a 1:55 PM ET. Se dispondrá de una transmisión en vivo y una repetición de la presentación de Canaccord en el sitio web de Immutep y a través de un enlace proporcionado.
Immutep (ASX: IMM; NASDAQ: IMMP), 암과 자가면역 질환을 위한 LAG-3 면역 요법에 중점을 둔 임상 단계의 생명공학 회사가 두 개의 투자자 회의에 참여할 것을 발표했습니다. 이 회사는 2024년 8월 14일 보스턴에서 열리는 캐나다 고투니티 제44회 연례 성장 회의와 2024년 9월 10일 뉴욕에서 열리는 베어드 2024 글로벌 헬스케어 회의에 발표합니다.
캐나다 고투니티 행사에서 Immutep의 발표는 오전 8:30에서 8:55 ET로 예정되어 있으며, 베어드 회의에서는 오후 1:25에서 1:55 ET에 발표됩니다. Immutep의 웹사이트 및 제공된 링크를 통해 캐나다 고투니티 발표의 실시간 웹캐스트와 다시보기를 이용할 수 있습니다.
Immutep (ASX: IMM; NASDAQ: IMMP), une entreprise biopharmaceutique en phase clinique spécialisée dans les immunothérapies LAG-3 pour le cancer et les maladies auto-immunes, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise présentera à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity à Boston le 14 août 2024 et à la Conférence Mondiale de Santé 2024 de Baird à New York le 10 septembre 2024.
Lors de l'événement Canaccord, la présentation d'Immutep est prévue de 8h30 à 8h55 ET, tandis qu'à la conférence de Baird, elle se présentera de 13h25 à 13h55 ET. Une diffusion en direct et un replay de la présentation Canaccord seront disponibles sur le site Web d'Immutep et via un lien fourni.
Immutep (ASX: IMM; NASDAQ: IMMP), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf LAG-3-Immuntherapien zur Behandlung von Krebs und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 44. Annual Growth Conference von Canaccord Genuity in Boston am 14. August 2024 und am Baird 2024 Global Healthcare Conference in New York am 10. September 2024 Präsentationen halten.
Auf der Canaccord-Veranstaltung ist die Präsentation von Immutep für 8:30-8:55 Uhr ET geplant, während das Unternehmen auf der Baird-Konferenz von 13:25 bis 13:55 Uhr ET präsentieren wird. Eine Live-Übertragung und eine Wiederholung der Präsentation von Canaccord werden auf der Website von Immutep und über einen bereitgestellten Link verfügbar sein.
- None.
- None.
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences:
| Canaccord Genuity 44th Annual Growth Conference | |
| Location: | InterContinental Boston Hotel, Boston, MA |
| Date: | Wednesday, 14 August 2024 |
| Time: | 08:30am – 8:55am ET |
| Baird 2024 Global Healthcare Conference | |
| Location: | InterContinental NY Barclay, New York, NY |
| Date: | Tuesday, 10 September 2024 |
| Time: | 01:25pm – 1:55pm ET |
A live webcast and replay of the presentation at the Canaccord Genuity conference will be available here and on the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
When and where will Immutep (IMMP) present at the Canaccord Genuity 44th Annual Growth Conference?
What is the date and time for Immutep's (IMMP) presentation at the Baird 2024 Global Healthcare Conference?
How can investors access Immutep's (IMMP) presentation at the Canaccord Genuity conference?
What is the focus of Immutep's (IMMP) research and development?
